On September 11, the FDA, Genentech and Biogen Idec (the manufacturers of Rituxan) announced that the labeling for the drug is being revised. This comes after the first report that a patient taking Rituxan to treat rheumatoid arthritis had died of the brain infection progressive multifocal leukoencephalopathy (PML). Rituxan is approved to treat RA and non-Hodgkins Lymphoma. Several cases of PML have previously been reported in patients taking Rituxan for unapproved, or off-label, uses,...
